Finding the signal in the serum — reading biotech results

There is a moment in every biotech small-cap story when the company announces a clinical trial result and the share price doubles. Or halves. For investors new to the sector, these swings feel arbitrary. For those who understand how biotech works, the logic is usually clear, even when the outcome is painful.

Reading a clinical trial result well is not a skill that requires a science degree. It requires understanding what the company was trying to prove, whether the trial was designed to prove it honestly, and whether the numbers actually show what the press release claims.

Biotech small-caps live and die by their clinical data. Unlike a mining company where you can examine drill results with some basic geology knowledge, biotech trial announcements use language specifically designed to be opaque to outsiders. The task for the investor is to learn enough to separate a genuine signal from a carefully crafted press release.

The first thing to understand is endpoint selection. Every clinical trial is designed around a primary endpoint, which is the specific outcome the drug needs to demonstrate to be considered successful. Companies choose their endpoints before the trial begins, and they are required to disclose what they are. That registration matters. If a company announces results that focus on a secondary endpoint while the primary endpoint missed, that is a significant red flag. It can happen that a drug shows interesting activity on a measure the trial was not designed to test, but that is not the same as a trial success and should not be presented as one.

Trial design matters as much as the results themselves. A well-designed trial is randomised and controlled, meaning patients are randomly assigned to receive either the treatment or a placebo, and neither the patients nor the doctors administering the treatment know which is which. This is called double-blind. Smaller trials can and do produce genuine evidence, but they are less robust. A Phase I trial is primarily a safety study. A Phase II trial tests efficacy in a small group, and a Phase III trial is the large, definitive test that regulators need to see before approving a drug for general use. An investor should always know which phase a company is in and understand that Phase I positive results are a starting point, not a finish line.

Peer-reviewed publication is another indicator that separates genuine science from promotional activity. When trial data is published in a reputable medical journal, it has been scrutinised by independent scientists. A press release, by contrast, has been written by the company’s communications team. If positive results have never been submitted for independent review, that absence is worth noting. Not every promising trial makes it to publication quickly, but a pattern of announcements that never receive external validation should put an investor on guard.

Management track record is often what separates the genuinely promising biotech from the perpetually hopeful one. Drug development is extraordinarily difficult, and the team leading it needs to have done it before. A chief medical officer who has taken a drug from Phase II through to regulatory approval brings a different quality of decision-making than one who has only worked in academia or early-stage research. Look at the management page and read the biographies carefully. The best biotech management teams have their own money in the company and have experienced failure before. Experience of failure is an asset in this sector, not a liability.

Partnership deals are one of the clearest external validation signals available to small-cap biotech investors. When a large pharmaceutical company agrees to co-develop or licence a drug, it has almost certainly carried out its own independent scientific assessment. Partnerships can take many forms, from a simple licensing agreement to a full co-development arrangement with milestone payments and royalties. The terms matter. A small upfront payment with large contingent milestones is very different from a substantial upfront payment that signals the partner’s genuine conviction. A meaningful partnership with a credible counterparty is not a guarantee of success, but it is confirmation that experts who have done their homework believe the science is real.

The distinction between a platform technology and a single-asset company carries significant implications for portfolio risk. A single-asset company has one drug, one trial and one binary outcome. If it works, the upside can be substantial. If it fails, the company may have little left. A platform company has a technology or biological mechanism that can potentially generate multiple drugs across multiple indications. The failure of a single programme is painful but not fatal. When evaluating a small-cap biotech, ask whether the company’s value rests entirely on one data readout, and calibrate your position size accordingly.

Cash runway is the financial metric that overrides almost everything else in early-stage biotech. A company with a promising drug and three months of cash is a company that will face a dilutive fundraise before it can finish the work. The typical biotech small-cap raises money repeatedly throughout its life because clinical trials are expensive and revenue is usually years away. Understand when the next significant spend will occur and whether the company has enough cash to reach the next meaningful milestone without a raise. Companies that consistently underestimate their cash needs tend to repeatedly dilute shareholders at the worst possible moments.

What happens when a lead asset fails is the real test of a biotech’s quality. Companies that have been honest about their pipeline depth and their financial position can survive a Phase III failure. Companies that have oversold a single programme and spent money carelessly usually cannot. The best biotech investors understand that failure is a feature of the sector, not an exception, and they build their positions with that in mind.

There is something genuinely exciting about investing in a company that is trying to solve a medical problem that has never been solved before. The potential is real, and small-caps have produced some of the most dramatic returns in the entire stock market. But those returns belong to investors who did the work rather than the ones who simply believed the press release.

This post is drawn from The Little Book of Small-Caps by Cameron Oliver. Republished with permission.

Small Caps is a series drawn from first-hand experience of UK and global small-cap markets, updated as each new chapter arrives.

Disclaimer: The value of investments can go down as well as up, and you may get back less than you invest. This article is for informational and educational purposes only and does not constitute financial advice. Always do your own research and consider seeking independent advice before making any investment decision.

This article is for informational purposes only and does not constitute financial advice. Investment values can go down as well as up. Always do your own research before making any financial decisions.